Sarepta Therapeutics Value Stock - Dividend - Research Selection
Sarepta Therapeutics
ISIN: US8036071004, WKN: A1J1BH
Market price: 75,65 USD
Sarepta Therapeutics Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 05-03-2021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 107.466.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -82.202.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 25.264.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 761.759.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 2.984.720.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | -554.128.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | -7,110 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 79.374.200 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 540.099.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | SRPT |
| Market Capitalization | 6.004.658.176,00 USD |
| Country | |
| Indices | NASDAQ Comp. |
| Sectors | |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2012-07-12,1.0000/6.0000 |
| Internet | www.sarepta.com |
Description of the company
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. It is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). It initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.